コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cated in the control of catagen (Bax, Bcl-2, insulin-like growth factor binding protein-3).
2 milar inverse associations were observed for insulin-like growth factor binding protein 3.
3 the presence of a protease directed against insulin-like growth factor binding protein 3.
4 tease activity specifically directed against insulin-like growth factor binding protein 3.
5 e genes, including glucose transporter-1 and insulin-like growth factor-binding protein 3.
6 746 was significantly associated with plasma insulin-like growth factor-binding protein-3.
7 iability in insulin-like growth factor-1 and insulin-like growth factor-binding protein-3.
8 levels; and age was strongly associated with insulin-like growth factor-binding protein-3.
9 nificant differences by supplement in plasma insulin-like growth factor-binding protein 3 (44 and 40
10 S/FLI1 decreased the transcript half-life of insulin-like growth factor binding protein 3, a down-reg
11 n binding of insulin-like growth factor-I to insulin-like growth factor binding protein 3 and the pre
12 factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein 3 and these l
13 tion of a specific protease directed against insulin-like growth factor binding protein 3 and to rela
14 characterized by down-regulation of Fas and insulin-like growth factor-binding protein 3 and by incr
16 tivates the insulin-response elements of the insulin-like growth factor-binding protein-3 and other i
17 tein 7, fibroblast growth factor receptor 2, insulin-like growth factor binding protein 3, and platel
19 ree thyroxine, insulin-like growth factor 1, insulin-like growth factor-binding protein 3, bone alkal
20 Whites had higher 25-hydroxyvitamin D and insulin-like growth factor binding protein 3 but lower 1
21 vity, serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrati
22 After 5 days, insulin-like growth factor binding protein 3 concentrati
23 increasing insulin-like growth factor-I and insulin-like growth factor binding protein 3 concentrati
24 Insulin-like growth factor binding protein 3 concentrati
25 g levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 early in cr
26 ced the anti-proliferative and pro-apoptotic insulin-like growth factor-binding protein-3 expression.
27 the potential apoptotic targets Bax and the insulin-like growth factor-binding protein 3 gene (IGF-B
28 uences derived from the bax promoter and the insulin-like growth factor-binding protein 3 gene (IGF-B
29 m the p53-responsive portions of the Bax and insulin-like growth factor-binding protein 3 gene promot
30 on between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) a
34 that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) w
35 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),
36 ons of insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),
37 growth factor type 1 and its carrier protein insulin-like growth factor binding protein 3 (IGFBP-3).
38 ular genes, including increased mRNA for the insulin-like growth factor binding protein 3 (IGFBP-3).
39 th factor I (IGF-I) and inversely related to insulin-like growth factor binding protein 3 (IGFBP-3).
40 owth factor binding protein 1 (IGFBP-1), and insulin-like growth factor binding protein 3 (IGFBP-3).
41 to determine whether Compound 49b stimulates insulin-like growth factor binding protein-3 (IGFBP-3) a
42 cts of insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3) a
43 n identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) a
46 d with IGF-II expression and positively with insulin-like growth factor binding protein-3 (IGFBP-3) e
48 from this laboratory revealed that vitreous insulin-like growth factor binding protein-3 (IGFBP-3) i
49 to increased endothelial cell expression of insulin-like growth factor binding protein-3 (IGFBP-3) i
52 NKX3.1 expression in PC-3 cells increased insulin-like growth factor binding protein-3 (IGFBP-3) m
53 nd RXR-specific ligands on the regulation of insulin-like growth factor binding protein-3 (IGFBP-3) p
56 gulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3).
57 of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) a
60 d plasminogen activator inhibitor-1 (PAI-1), insulin-like growth factor-binding protein 3 (IGFBP-3),
61 Insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) a
62 The hepatic expression and serum levels of insulin-like growth factor-binding protein-3 (IGFBP-3) a
65 er retinoic acid receptor-beta (RARbeta) nor insulin-like growth factor-binding protein-3 (IGFBP-3) i
67 e same cells exhibited dramatic increases in insulin-like growth factor-binding protein-3 (IGFBP-3) m
70 identified in patients with ARDS, including insulin-like growth factor-binding protein-3 (IGFBP-3).
71 ng growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) a
72 secretome proteomics approach, we identified insulin-like growth factor binding protein 3 (IGFBP3) as
73 or induction of the proapoptotic target gene insulin-like growth factor binding protein 3 (IGFBP3) by
74 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a
75 ugh a previously unappreciated activation of insulin-like growth factor binding protein 3 (IGFBP3), w
77 ltered in the Id cKO hearts, but addition of Insulin-Like Growth Factor binding protein-3 (IGFbp3) re
79 asked whether the hypoxia-regulated factor, insulin-like growth factor binding protein-3 (IGFBP3), c
81 for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), D
82 evels and the induction of wild-type p53 and insulin-like growth factor-binding protein-3 (IGFBP3) 24
83 of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 in 6,520 wo
84 pression of p53 target genes, p21(waf-1) and insulin-like growth factor binding protein 3 in glioma c
85 mulation (up to 5.8 fold; P < 0.05) of human insulin-like growth factor-binding protein-3 in mouse pl
86 ulin-like growth factor-I and restoration of insulin-like growth factor binding protein-3 levels, and
87 854746 is also significantly associated with insulin-like growth factor-binding protein-3 levels in t
88 ciated with insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels; Acu
90 ase in plasminogen activator inhibitor-I and insulin-like growth factor binding protein-3 mRNA levels
91 insulin-like growth factor-1 (P < 0.03) and insulin-like growth factor binding protein-3 (P < 0.02)
92 included serum insulin-like growth factor-1, insulin-like growth factor binding protein-3, prolactin,
93 onsurvivor, insulin-like growth factor-I and insulin-like growth factor binding protein 3 remained lo
95 ssion of connective tissue growth factor and insulin-like growth factor binding protein-3 was observe
96 trations of insulin-like growth factor-I and insulin-like growth factor binding protein 3 were higher
97 esence of protease activity directed against insulin-like growth factor binding protein 3 were invest
98 a survivor, insulin-like growth factor-I and insulin-like growth factor binding protein 3 were low in
99 messenger RNAs for the IGF-I transgene, and insulin-like growth factor-binding protein 3 were assaye
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。